Back to search results

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

Abroad (travel likely)RecruitingPHASE2

Conditions

NSCLC · Brain Metastases · ROS1 Gene Rearrangement

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Medizinische Universität Graz, Graz, Austria

  • Medical University of Vienna, Vienna, Austria

  • Ludwig-Maximilians-University Munich, München, Germany

  • Hospital de Vinalopó, Elche, Alicante, Spain

  • Hospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain

  • Hospital General Universitario Dr. Balmis, Alicante, Spain

  • Hospital de Cruces, Barakaldo, Spain

  • UOMI Cancer Center, Barcelona, Spain

  • Hospital Universitari Vall d'Hebron, Barcelona, Spain

  • Institut Català d' Oncologia Girona (ICO), Girona, Spain

  • Hospital Universitario de León, León, Spain

  • Hospital Lucus Agusti, Lugo, Spain

  • Hospital Beata María Ana, Madrid, Spain

  • Hospital Universitario Vithas Madrid La Milagrosa, Madrid, Spain

  • Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain

  • Hospital Clínico Universitario de Valencia, Valencia, Spain

Study leads

  • Matthias Preusser, md

    Principal Investigator

    Medical University of Vienna, Vienna General Hospital (Austria)

  • Barbara Kiesewetter, MD

    Principal Investigator

    Medical University of Vienna, Vienna General Hospital (Austria)

  • Thorsten Füreder, MD

    Principal Investigator

    Medical University of Vienna, Vienna General Hospital (Austria)

View source on ClinicalTrials.gov(opens in a new tab)